Treatment of hypersexuality and benign prostatic hypertrophy with delmadinone acetate in intact male dogs

Authors : Hakkı B. BECERİKLİSOY, Serhan S. AY, Duygu KAYA, Ali R. AĞAOĞLU, İbrahim KÜÇÜKASLAN

Pages : 25-31

View : 13 | Download : 3

Publication Date : 0000-00-00

Article Type : Research Paper

Abstract :The aim of the present study was to evaluate the effectiveness of delmadinone acetate insert ignore into journalissuearticles values(DMA); for the treatment of hypersexuality insert ignore into journalissuearticles values(HS); and benign prostatic hypertrophy insert ignore into journalissuearticles values(BPH);, which are frequently observed in male dogs, for which no surgical treatment has been indicated. The study was performed with 21 intact male dogs that had HS insert ignore into journalissuearticles values(n = 12); and signs of BPH insert ignore into journalissuearticles values(n = 9);. DMA insert ignore into journalissuearticles values(Tardak® or Tardastrex®); was administered subcutaneously to each dog at a dose of 3-5 mg/kg and was repeated 15 days later as a second treatment. DMA administration was repeated in some cases until the clinical signs disappeared. The successful recovery rate of HS cases was found to be 50% after a single application and 25% by the second and third applications. The mean `recovery periods` and mean `stable periods` of these 3 consecutive applications were found to be 5.83, 7.66, and 6.00 days, and 16.7, 18.7, and 20.0 months, respectively. With regard to BPH after consecutive applications, treatment success rates, mean recovery periods, and mean stable periods were 33.3%, 22.2%, 44.4%, 12.0, 11.0, 9.5 days, and >30, 12, and 13.5 months, respectively. DMA is clinically applicable as a therapeutic agent for HS and BPH cases; however, repeated applications were required due to temporary recoveries.
Keywords : Key words Clinical application, prostate, repeated doses, therapeutic agent